Rather than dampening demand, pharmaceutical supply challenges present opportunities for innovation to transport specialists.

Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology.

Samsung Bioepis has now allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous ...

Entrada Therapeutics can plough on with the development of its Duchenne muscular dystrophy (DMD) therapy, ENTR-601-44, now ...

The EMA has granted approval for an additional 2 mL pre-filled pen option for Takeda’s Takhzyro, aimed at treating HAE.

In an anonymous post in the BMJ, the author claims that words relating to DEI could lead to grants being taken away.

Gilead Sciences has announced EMA validation for a parallel accelerated review of lenacapavir’s MAA and EU-M4all applications ...

Sionna Therapeutics recently secured an initial public offering (IPO) of $191m on the Nasdaq stock exchange, signalling ...

The FDA has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence application (sBLA) for Opdivo and Yervoy ...